



(11)

EP 2 986 714 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
06.01.2021 Bulletin 2021/01

(51) Int Cl.:
A61P 3/00 (2006.01) **A61P 3/04 (2006.01)**
A61P 3/10 (2006.01) **C12N 5/077 (2010.01)**

(21) Application number: **14729769.1**

(86) International application number:
PCT/US2014/034540

(22) Date of filing: **17.04.2014**

(87) International publication number:
WO 2014/172561 (23.10.2014 Gazette 2014/43)

(54) **HUMAN BROWN ADIPOSE DERIVED STEM CELLS AND USES**

STAMMZELLEN AUS MENSCHLICHEM BRAUNEN FETTGEWEBE UND VERWENDUNGEN

CELLULES SOUCHES DÉRIVÉES DU TISSU ADIPEUX BRUN HUMAIN ET LEURS UTILISATIONS

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **19.04.2013 US 201361813771 P**
19.11.2013 US 201361906087 P

(43) Date of publication of application:
24.02.2016 Bulletin 2016/08

(60) Divisional application:
20204990.4

(73) Proprietors:

- **Biorestoreative Therapies, Inc.**
 Melville, NY 11747 (US)
- **Silva, Francisco, Javier**
 Miramar, FL 33027 (US)

(72) Inventor: **SILVA, Francisco Javier**
Miramar, Florida 33027 (US)

(74) Representative: **Reichert & Lindner**
Partnerschaft Patentanwälte
Stromerstr. 2A
93049 Regensburg (DE)

(56) References cited:
WO-A1-2009/156413

- **PATEL AMIT N ET AL:** "Putative Population of Adipose-Derived Stem Cells Isolated From Mediastinal Tissue During Cardiac Surgery", **CELL TRANSPLANTATION**, vol. 22, no. 3, 2 April 2012 (2012-04-02), pages 507-511, XP002726920,
- **ARTURO HERNANDEZ ET AL:** "Dexamethasone Inhibits Growth Factor-Induced Type 3 Deiodinase Activity and mRNA Expression in a Cultured Cell Line Derived from Rat Neonatal Brown Fat Vascular-Stromal Cells", **ENDOCRINOLOGY**, vol. 143, no. 7, 1 July 2002 (2002-07-01), pages 2652-2658, XP055127771, ISSN: 0013-7227, DOI: 10.1210/endo.143.7.8923
- **M. CIGOLINI ET AL:** "Human brown adipose cells in culture", **EXPERIMENTAL CELL RESEARCH**, vol. 159, no. 1, 1 July 1985 (1985-07-01), pages 261-266, XP055040049, ISSN: 0014-4827, DOI: 10.1016/S0014-4827(85)80056-2
- **TIM J SCHULZ ET AL:** "Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat", **PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US**, vol. 108, no. 1 4 January 2011 (2011-01-04), pages 143-148, XP002675155, ISSN: 0027-8424, DOI: 10.1073/PNAS.1010929108 Retrieved from the Internet:
[URL: http://www.pnas.org/content/108/1/143](http://www.pnas.org/content/108/1/143)
[retrieved on 2010-12-20]

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- KLEIN J ET AL: "Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action", BIOESSAYS, JOHN WILEY & SONS LTD, GB, vol. 24, 1 January 2002 (2002-01-01), pages 382-388, XP003005168, ISSN: 0265-9247, DOI: 10.1002/BIES.10058
- FRANCISCO J SILVA ET AL: "Metabolically Active Human Brown Adipose Tissue Derived Stem Cells", STEM CELLS, vol. 32, no. 2, 13 February 2014 (2014-02-13), pages 572-581, XP055127776, ISSN: 1066-5099, DOI: 10.1002/stem.1595
- Pontus Boström ET AL: "A PGC1-[alpha]-dependent myokine that drives brown-fat-like development of white fat and thermogenesis", Nature, vol. 481, no. 7382, 1 January 2012 (2012-01-01), pages 463-468, XP055052526, ISSN: 0028-0836, DOI: 10.1038/nature10777

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description**RELATED APPLICATIONS**

[0001] This application claims priority to US Provisional applications 61/906,087 and 61/813,771 which were filed on November 19, 2013 and April 19, 2013, respectively;

FIELD OF THE INVENTION

[0002] The invention relates generally to the field of cell culture and more specifically to the field of determining cell type.

BACKGROUND OF THE INVENTION

[0003] Brown adipose tissue (BAT) plays a key role in the evolutionarily conserved mechanisms underlying energy homeostasis in mammals. It is characterized by fat vacuoles 5-10 microns in diameter and expression of uncoupling protein 1 (UCP1), central to the regulation of thermogenesis. In the human newborn, depots of BAT are typically grouped around the vasculature and solid organs. These depots maintain body temperature during cold exposure by warming the blood before its distribution to the periphery. They also ensure an optimal temperature for biochemical reactions within solid organs. BAT had been thought to involute throughout childhood and adolescence. Recent studies, however, have confirmed the presence of active brown adipose tissue in adult humans, with depots residing in cervical, supraclavicular, mediastinal, paravertebral and/or suprarenal regions, for example. Also, it has also been reported that BAT, alternatively called beige fat can be found within white adipose tissue (WAT). PATEL AMIT N ET AL, "Putative Population of Adipose-Derived Stem cells Isolated From Mediastinal Tissue During Cardiac Surgery", CELL TRANSPLANTATION, vol. 22, no. 3, 2 April 2012 (2012-04-02), pages 507-511, discloses a mesenchymal stem cell population isolated from mediastinal adipose depots.

[0004] Pontus, Bostrom et al, "A PGC1- α -dependent myokine that drives brown-fat-like development of white fat and thermogenesis", Nature, vol. 481, No. 7382, January 1, 2012, pages 463-468, describes human adult brown adipose tissue differentiated cells derived from isolated human adult brown adipose tissue stem cells.

SUMMARY

[0005] The invention relates in part to an isolated human brown adipose tissue stem cell line isolated from a one day old male neonate. In one embodiment, the isolated human brown adipose tissue stem cell line expresses markers such as CREB1, DIO2, IRS1, MAPK14, NRF1, FOXC2, PPARD, PGC1-A, PGC1-B, PRDM16, SRC, UCP1, and WNT5A. In another embodiment, the cells also express higher levels of anti-white adipose tis-

sue genes, such as GATA2, KLF2, and KLF3. In still another embodiment, the isolated human brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes. In still yet another embodiment, the line is derived from a one day old male neonate.

BRIEF DESCRIPTION OF THE DRAWINGS

[0006] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The present teachings described herein will be more fully understood from the following description of various illustrative embodiments, when read together with the accompanying drawings. It should be understood that the drawings described below are for illustration purposes only and are not intended to limit the scope of the present teachings in anyway.

Fig. 1 is a PET scan of 18F-FDG uptake in an adult;

Fig. 2(a) is a photograph of mediastinal adipose tissue from a neonate;

Fig. 2(b) is a photograph of mediastinal adipose tissue from a 56 year old;

Fig. 2(c) is a photograph of mediastinal adipose tissue from an 80 year old;

Fig. 2(d) is a photomicrograph of a section of the tissue of Fig. 2(a);

Fig. 2(e) is a photomicrograph of a section of the tissue of Fig. 2(b);

Fig. 2(f) is a photomicrograph of a section of the tissue of Fig. 2(c);

Fig. 3(a) is a series of flowcytometry and immunocytochemistry graphs for cell surface markers on neonatal brown adipose derived stem cells;

Fig. 3(b) is a table of comparisons of expression levels for various markers for neonatal brown adipose derived stem cells and white adipose derived stem cells;

Fig. 3(c) is a gene expression profile for neonatal brown adipose derived stem cells (BADSC) and white adipose derived stem cells (WADSC);

Fig. 4(a) is a scanning electron microscopy (SEM) of brown adipose derived stem cells cultured on porous extracellular matrix scaffolds;

Fig. 4(b) is an SEM of directionally differentiated brown adipocytes on scaffolds;

Fig. 5(a) is a map of a first transformation construct used to immortalize neonatal brown adipose derived stem cells;

Fig. 5(b) is a map of a second transformation construct used to immortalize neonatal brown adipose derived stem cells;

Fig. 5(c) is a map of a third transformation construct used to immortalize neonatal brown adipose derived stem cells;

Fig. 5(d) is a map of a fourth transformation construct used to immortalize neonatal brown adipose derived stem cells;

Fig. 5(e) is a map of a fifth transformation construct used to immortalize neonatal brown adipose derived stem cells;

Fig. 6 is a graph of cell growth rate by passage;

Fig. 7 is a graph of telomerase activity for transfected and control cells;

Fig. 8 is a photomicrograph of transfected BADSC showing normal cell morphology;

Fig. 9 is a photomicrograph of BADSC having undergone white, brown adipogenesis;

Fig. 10 is a photomicrograph of BADSC having undergone osteogenesis;

Fig. 11 is a photomicrograph of BADSC having undergone chondrogenesis;

Fig. 12(a) is a graph of glucose levels of mice transplanted with BADSC/scaffolds and controls;

Fig. 12(b) is a graph of the weights of mice transplanted with BADSC/scaffolds and controls; and

Fig. 13 is a depiction of the steps for high throughput analysis of compounds.

DETAILED DESCRIPTION

[0007] A population of metabolically active brown adipose tissue stem cells has been isolated from a one day old male new born. The stem cell population, termed "neonate brown adipose derived stem cells" (neonate BADSCs) demonstrated the potential to: (1) be expanded *in vitro*; (2) exhibit multi-lineage potential; and (3) functionally differentiate into metabolically active brown adi-

pocytes. Such a stem cell population could offer new cell-based means to restore and enhance energy homeostasis *in vivo* for the treatment of obesity and related metabolic disorders. These stem cells also are a useful tool for studying adipose tissue biology.

[0008] In order to identify a stem cell population within newborn mediastinal brown adipose depots, explants were generated and plated into tissue culture plates. Adherent cells were successfully derived from the brown adipose tissue explants, these primary cell cultures were fed every 3 days in media comprising DMEM low glucose, 1x Glutamax, 1x NEAA, and 10% platelet lysate. In order to define a clonal population of cells, cell lines were derived by single-cell plating in 96 well plates. Confluence was reached at 6 days and the cells exhibited Mesenchymal Stem Cell (MSC)-like morphology, as depicted in Fig. 8. Mediastinal brown adipose tissue from a 56 year old and an 80 year old are shown in Figs. 2b and 2c, respectively, for comparison with the newborn mediastinal brown adipose tissue, as depicted in Fig. 2a. The decrease in the brown adipose tissue is evident. Figs. 2d-2f are photomicrographs of H/E sections taken of the biopsied tissues of Figs. 2a-2c, respectively.

[0009] Growth kinetics of the clonal cell population demonstrated that the population could be propagated for greater than 90 passages. Karyotyping of the clonal cell population at passage 7 demonstrated normal diploid cells without chromosomal aberrations.

[0010] Referring to Figs. 3(a) and (3b), to further characterize these neonate BADSC, flow cytometry, and immunocytochemistry were used. The neonate BADSC were found to exhibit characteristics that are similar to other MSCs but are not identical. For instance, the neonate BADSC were positive for CD9, SSEA4, CD44, CD90, CD166, and CD73, but were negative for hematopoietic markers CD14, CD34, and CD45. Furthermore, the neonate BADSC did not express STRO-1, which has been previously found to be expressed in mesenchymal stem cells derived from various tissues.

[0011] An analysis of the gene expression profiles of passage 2 neonate BADSC demonstrate that the neonate BADSC have a distinct gene expression profile, as depicted in Fig. 3(c), in comparison with white adipose derived stem cells. The genes whose expression is enriched in BADSC include pro-brown adipose selective genes such as, for example, CREB1, DIO2, IRS1, MAPK14, NRF1, FOXC2, PPARD, PGC1-A, PGC1-B, PRDM16, SRC, UCP1, and WNT5A. The cells also express higher levels of anti-white adipose tissue genes, such as GATA2, KLF2, and KLF3. Importantly, expression of these pro-brown selective genes can distinguish brown adipose derived stem cells from stem cells derived from white adipose depots.

[0012] Passage 2 neonate BADSC were induced to differentiate into osteo, chondro, white, and brown adipogenic cell lineages to determine multi-lineage potential. After three weeks of induction the cells demonstrated the ability to differentiate into osteoblasts, chondrocytes,

and adipocytes. When induced to differentiate under osteogenic promoting conditions, the cells formed a mineralized matrix, which was confirmed by alizarin red staining; immunocytochemistry staining of osteocalcin, and RT-PCR analysis for osteopontin, osteonectin, and alkaline-phosphatase, further confirmed differentiation. Chondrogenic differentiation was confirmed by alcian blue staining for sulfated proteoglycans on induced cell pellets. RT-PCR confirmed expression of collagen 2A, biglycan, and A6, which are markers of chondrogenic differentiation. White adipogenic differentiation was confirmed by Oil Red O staining of lipid droplets. Immunocytochemistry confirmed expression of FABP4, and RT PCR confirmed expression of FABP4, LPL, and PPAP γ , which are markers of adipogenic differentiation.

[0013] Real-time qPCR of neonatal brown adipose-differentiated cells demonstrated upregulation of UCP1, elongation of very long chain fatty acids like-3 (ELOVL3) and peroxisome proliferator-activated receptor γ 1- α (PGC1A), a major regulator of mitochondrial biogenesis, compared to non-FNDC5 differentiated cells. Conversely, leptin--a gene associated with white fat development--is down regulated in brown-adipose differentiated cells. Higher levels of expression of these brown adipocyte marker genes are consistent with a mature brown adipocyte fate. These findings demonstrate that brown adipose depots from newborns are a source of stem cells that have unique properties than stem cells found in adult brown adipose depots, subcutaneous adipose and visceral adipose depots, and have the ability to differentiate into multiple cell types.

[0014] BADSC in general can be grown on scaffolding as, as depicted in Fig. 4(a), and thereby made more easily handled for implantation and other experimentation.

[0015] In addition, various BADSC lines were immortalized by transfection. In one embodiment a BADSC150 line was used.

[0016] Five different plasmid constructs were created, as depicted in Figs. 5(a)-5(e). These were a 7286 bp construct termed Blas-T, encoding an EEF1 promoter driving TERT expression, a 4868 bp construct termed Blas-B, encoding an EEF1 promoter driving BMI-1 expression; an 8348 bp construct termed Blas-B-F-T, encoding an EEF1 promoter driving both BMI1 and TERT expression, an 8348 bp construct termed pBlas-BIT encoding an EEF1 promoter driving both TERT and BsrS2, and a 16,243 bp construct termed pUCP1-CP-BfT encoding an EEF1A1 promoter driving expression of BMI1 and TERT and UCP1 promoter driving expression of a reporter gene cherry picker.

[0017] In one embodiment, the transfection used Lipofectamine LTX and PLUS reagent. In a second embodiment, the transfection used Fugene HD, Xfect Adult Stem Cell Transfection Reagent and Lipofectamine LTX with PLUS reagent according to manufacturers recommended protocol. Each reagent was tested for efficiency. Fugene HD was the least toxic to the cells and resulted in the highest transfection efficiency for BADSC150 pri-

mary cells transfected with construct Blas-BfT encoding EEF1 promoter driving expression of BMI1 and TERT (BMI1-TERT FMDV2-self processing polypeptide and TERT-BMI1 FMDV2-self processing polypeptide). Because the two orientations of the self processing polypeptides will function with differing efficiencies depending upon the cell line, both forms were tested in any given experiment.

[0018] In other embodiments, the BADSC150 line was transfected with the following combination of constructs listed below. The transfected cells with the blastocidin resistance gene were selected with a concentration of 6ug/ml. blastocidin. A stable immortalized brown adipose derived stem cell line was generated and tested for functional differentiation potential.

[0019] Under EEF1A1 control, all four resistance options were available:

pUNO-hpf Hygromycin;
pUNO-pur Puromycin;
pUNO-zeo Zeocin; and
pUNO-bla Blasticidin

[0020] The following single reporter systems were used:

*mCherry alone;
*NanoLuc (NL) alone; and
*Secreted NanoLuc (sNL) alone.

[0021] The following combination Reporter systems were also used:

CP1-NL FMDV2-self processing polypeptide;
CP1-sNL FMDV2-self processing polypeptide;
NL-CP1 FMDV2-self processing polypeptide; and
sNL-CP1 FMDV2-self processing polypeptide.

[0022] In other experiments, the EEF1 promoter was also replaced with pro-brown (i.e. PRDM16, PGC-1 α , C/EBP β , Plac8 and UCP-1) and pro-white specific genes (i.e. PPAR γ , C/EBP α , and AKT-1) used with different combinations of the reporter systems. All of these constructs contain EEF1 promoter driving expression of BMI1 and TERT.

[0023] Once the BDSC150 cell line was transfected and selected, it was tested to determine the effects of extended passages. BADSC150 BMI1-TERT FMDV2-self processing polypeptide (Fig. 5(d)) and TERT-BMI1 FMDV2-self processing polypeptide were passaged to p20 (Fig. 6). Cells expressed telomerase activity (Fig. 7) which was not present in the control (non-transfected BADSC150) and retained normal cell morphology (Fig. 8).

[0024] Immortalized BADSC150 cells were also tested to determine their ability to functionally differentiate. Cells were induced to undergo white, brown adipogenesis (Fig. 9), osteogenesis (Fig. 10) and chondrogenesis (Fig. 11).

This cell line with the different combinations of these constructs can be used to screen libraries of small molecules and brown adipose inducers (i.e. FNDC5, BMP7, retinoic acid).

[0025] In one combination, where the construct is UCP1-CherryPicker BfT, (Fig. 5(c)), EEF1A1 is driving the expression of Bmil and Tcrtl. This construct is used to immortalize the cells. UCP1 is driving the expression of CherryPicker, chimeric membrane-anchored CherryPicker fluorescent protein, which can be monitored via fluorescence microscopy and be captured on magnetic beads using a specific antibody. In this embodiment, BADSC150 cells with this construct are immortal and CherryPicker is only activated when UCP1 is induced. The induction of UCP1 can be accomplished by exposing this cell population to either naturally occurring or synthetic small molecules that up-regulate brown adipose tissue specific genes.

[0026] In another embodiment, CherryPicker is replaced with secreted nanoluc (sNL). In this construct, sNL is synthesized only when the promoter is turned "ON". In one embodiment, the promoter is UCP1. Since sNL is secreted from the cell and into the cell culture media, one is able to assay the media for levels of sNL for a quantitative analysis of how efficacious the compound is for inducing UCP1 to turn "on" and in turn produce sNL. This system allows for high throughput screening of thousands of small molecules at different concentrations at one time.

[0027] All combinations of constructs also have been transfected into white adipose stem cells for the purpose of identifying molecules that convert white fat into brown or increase metabolic activity. This cell line, in tandem with its reporter systems, permits for the effective study of the kinetics of brown fat biology; specifically, the mechanism underlying UCP1 up-regulation and increased metabolic activity. This human brown fat stem cell line is valuable due to the fact that the amino acid composition of mouse and human UCP1 is less than 80%, thereby rendering mouse brown fat cell lines inadequate for identifying compounds that activate brown fat specific genes

[0028] In addition, a population of immortal implantable BADSC would provide a population of brown adipose tissue that can help regulate metabolism in humans. Referring to Figs. 12(a) and 12(b), the two graphs show the effects of BADSC on scaffolds implanted in mice. Fig. 12(a) shows that in the weeks after implantation, the basal blood glucose levels for control mice fed with a high calorie diet are significantly higher (about 66%) than mice fed with the same diet but implanted with BADSC. Similarly, in Fig. 12(b) the body weight for the control mice is about 40% higher than the body weight of the mice with an implant. This indicates that BADSC may be useful in treating metabolic disorders such as diabetes and obesity.

[0029] The invention also provides a cell culture plate comprising human neonatal brown adipose derived cells. The plate can be, for example, a multiwell plate. One or

more wells of the cell culture plate can be seeded with human neonatal brown adipose derived cells. The cells can be differentiated brown fat cells. The cells also can be immortalized. The cell culture plates are useful for screening drug compounds by contacting the cells with a candidate drug compound and observing the effect of the drug compound on the human neonatal brown adipose derived cell.

[0030] Referring to Fig. 13, such a screening method for various potential drugs begins by plating wells with either transfected BADSC cells (such as BADSC150FS. UCP1-sNL-BfT) or white adipose stem cells (such as WADSCFS. UCP1-sNL-BfT) (Step 1). Then the compounds of interest are added to the well (Step 2) and the wells are read in a plate reader and the media assayed for secreted nanoluc (Step 3), for example. The presence of nanoluc indicates that the drug has activated the stem cells.

[0031] It is to be understood that the figures and descriptions of the invention have been simplified to illustrate elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements. Those of ordinary skill in the art will recognize, however, that these and other elements may be desirable. However, because such elements are well known in the art, and because they do not facilitate a better understanding of the invention, a discussion of such elements is not provided herein. It should be appreciated that the figures are presented for illustrative purposes and not as construction drawings. Omitted details and modifications or alternative embodiments are within the purview of persons of ordinary skill in the art.

[0032] The invention may be embodied in other specific forms. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.

Claims

- 45 1. An isolated human brown adipose tissue stem cell line,
characterized in that
the isolated human brown adipose tissue stem cell line is neonatal and capable of differentiating into neonatal brown adipose differentiated cells in culture medium comprising fibronectin type III domain-containing protein 5 (FNDC5);
wherein UCP-1, ELOVL3, and PGC1A gene expression is upregulated in the neonatal brown adipose differentiated cells compared to non-fibronectin type III domain-containing protein 5 (FNDC5) differentiated cells.

2. The isolated human neonatal brown adipose tissue stem cell line of claim 1 wherein the isolated human neonatal brown adipose tissue stem cell line is derived from a one day old male neonate.
3. The isolated human neonatal brown adipose tissue stem cell line of claim 1, wherein the isolated human neonatal brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
4. The isolated human neonatal brown adipose tissue stem cell line of claim 1, further expressing at least one of the genes selected from the group consisting of:
CREB1, DIO2, IRS1, MAPK14, NRF1, FOXC2, PP-ARD, PGC1-A, PGC1-B, PRDM16, SRC, UCP1, and WNT5A.
5. The isolated human neonatal brown adipose tissue stem cell line of claim 4 wherein the isolated human neonatal brown adipose tissue stem cell line is derived from a one day old male neonate.
6. The isolated human neonatal brown adipose tissue stem cell line of claim 4, wherein the isolated human neonatal brown adipose tissue stem cell is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
7. The isolated human neonatal brown adipose tissue stem cell line of claim 1, further expressing at least one of the genes selected from the group consisting of:
UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, and WNT5A (REFX).
8. The isolated human neonatal brown adipose tissue stem cell line of claim 7 wherein the isolated human neonatal brown adipose tissue stem cell line is derived from a one day old male neonate.
9. The isolated human neonatal brown adipose tissue stem cell line of claim 7, wherein the isolated human neonatal brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
10. The isolated human neonatal brown adipose tissue stem cell line of claims 1, 4, or 7, wherein the isolated human neonatal brown adipose tissue stem cell line is positive for the following cell surface markers: CD9, SSEA4, CD44, CD90, CD166, and CD73, and is negative for the following cell surface markers: CD14, CD34, CD45, and STRO-1.
11. The isolated human neonatal brown adipose tissue stem cell line of claim 10 wherein the isolated human neonatal brown adipose tissue stem cell line is derived from a one day old male neonate.
- 5 12. The isolated human neonatal brown adipose tissue stem cell line of claim 10, wherein the isolated human neonatal brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
- 10 13. The isolated human neonatal brown adipose tissue stem cell line of claims 1, 4, 7, or 10, wherein the isolated human neonatal brown adipose tissue stem cell line is immortalized.
- 15 14. The isolated human neonatal brown adipose tissue stem cell line of claim 1, 4, 7, 10, or 13, wherein the isolated human neonatal brown adipose tissue stem cell line is transfected.
- 20 15. The isolated human neonatal brown adipose tissue stem cell line of claims 1, 4, 7, 10, 13, or 14 further expressing at least one of the genes selected from the group consisting of: GATA2, KLF2, and KLF3.
- 25 16. The isolated human brown adipose tissue stem cell line according to anyone of claims 1 to 15 for use in treating a metabolic disorder, for example obesity and/or diabetes, in a patient, wherein the cell line is cultured on a scaffold, such as a porous extracellular matrix.
- 30 17. A method of screening drug compounds, the method comprising:
providing the isolated human neonatal brown adipose tissue stem cell line of anyone of claims 1 to 16;
contacting the isolated human neonatal brown adipose tissue stem cell with a candidate drug compound; and
observing the effect of the drug compound on the isolated human neonatal brown adipose tissue stem cell.
- 35 18. The method of claim 17, wherein the isolated human neonatal brown adipose tissue stem cell line is immortalized.
- 40 19. An implantable construct, comprising:
a scaffold; and
the isolated human neonatal brown adipose tissue stem cell line of anyone of claims 1 to 15 cultured on the scaffold.
- 45 50 55 20. The implantable construct of claim 19 wherein the scaffold comprises a porous extracellular matrix.

Patentansprüche

1. Isolierte Stammzelllinie aus menschlichem braunen Fettgewebe,
dadurch gekennzeichnet, dass
 die isolierte Stammzelllinie aus menschlichem braunen Fettgewebe neonatal ist und in der Lage ist, sich in einem Kulturmedium, das FNDC5 (Fibronectin Type III Domain-Containing Protein 5) enthält, zu differenzierten neonatalen braunen Fettzellen zu differenzieren;
 wobei eine UCP-1-, ELOVL3- und PGC1A-Genexpression in den differenzierten neonatalen braunen Fettzellen im Vergleich zu nicht-FNDC5(Fibronectin Type III Domain-Containing Protein 5)-differenzierten Zellen hochreguliert ist.
2. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe von einem einen Tag alten männlichen Neugeborenen abstammt.
3. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe in der Lage ist, sich zu Osteoblasten, Chondrozyten und Adipozyten zu differenzieren.
4. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, die ferner mindestens eines der Gene, ausgewählt aus der Gruppe bestehend aus CREB1, DIO2, IRS1, MAPK14, NRF1, FOXC2, PPARD, PGC1-A, PGC1-B, PRDM16, SRC, UCP1 und WNT5A, exprimiert.
5. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 4, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe von einem einen Tag alten männlichen Neugeborenen abstammt.
6. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 4, wobei die isolierte Stammzelle aus menschlichem neonatalen braunen Fettgewebe in der Lage ist, sich zu Osteoblasten, Chondrozyten und Adipozyten zu differenzieren.
7. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, die ferner mindestens eines der Gene, ausgewählt aus der Gruppe bestehend aus UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3 und WNT5A (REFX), exprimiert.
8. Isolierte Stammzelllinie aus menschlichem neona-
- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
- talen braunen Fettgewebe nach Anspruch 7, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe von einem einen Tag alten männlichen Neugeborenen abstammt.
9. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 7, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe in der Lage ist, sich zu Osteoblasten, Chondrozyten und Adipozyten zu differenzieren.
10. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, 4 oder 7, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe positiv für die folgenden Zelloberflächenmarker ist: CD9, SSEA4, CD44, CD90, CD166 und CD73, und negativ für die folgenden Zelloberflächenmarker ist: CD14, CD34, CD45 und STRO-1.
11. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 10, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe von einem einen Tag alten männlichen Neugeborenen abstammt.
12. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 10, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe in der Lage ist, sich zu Osteoblasten, Chondrozyten und Adipozyten zu differenzieren.
13. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, 4, 7 oder 10, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe immortalisiert ist.
14. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, 4, 7, 10 oder 13, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe transfiziert ist.
15. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach Anspruch 1, 4, 7, 10, 13 oder 14, die ferner mindestens eines der Gene, ausgewählt aus der Gruppe bestehend aus GATA2, KLF2 und KLF3, exprimiert.
16. Isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach einem der Ansprüche 1 bis 15, zur Verwendung bei der Behandlung einer Stoffwechselstörung, beispielsweise Fettleibigkeit und / oder Diabetes, bei einem Patienten, wobei die Zelllinie auf einem Zellträger, beispielsweise

- einer porösen extrazellulären Matrix, kultiviert wird.
17. Verfahren zum Screenen von Arzneimittelverbindungen, wobei das Verfahren umfasst:
- 5 Bereitstellen der isolierten Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach einem der Ansprüche 1 bis 16; Inkontaktrbringen der isolierten Stammzelle aus menschlichem neonatalen braunen Fettgewebe mit einem Arzneimittelkandidaten; und Beobachten der Wirkung der Arzneimittelverbindung auf die isolierte Stammzelle aus menschlichem neonatalen braunen Fettgewebe.
18. Verfahren nach Anspruch 17, wobei die isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe immortalisiert ist.
19. Implantierbares Konstrukt, umfassend:
- 20 einen Zellträger; und die auf dem Zellträger kultivierte isolierte Stammzelllinie aus menschlichem neonatalen braunen Fettgewebe nach einem der Ansprüche 1 bis 16.
20. Implantierbares Konstrukt nach Anspruch 19, wobei der Zellträger eine poröse extrazelluläre Matrix umfasst.
- Revendications**
1. Lignée de cellules souches de tissu adipeux brun humain isolé, **caractérisée en ce que** la lignée de cellules souches de tissu adipeux brun humain isolé est néonatale et capable de se différencier en cellules différencierées de tissu adipeux brun néonatal dans un milieu de culture comprenant une protéine 5 contenant un domaine de fibronectine de type III (FNDC5) ; dans laquelle l'expression génique de UCP-1, ELOVL3, et PGC1A est régulée à la hausse dans les cellules différencierées de tissu adipeux brun néonatal en comparaison à des cellules différencierées de protéine 5 ne contenant pas de domaine de fibronectine de type III (FNDC5).
 2. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 1, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est dérivée d'un nouveau-né de sexe masculin âgé d'un jour.
 3. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 1, dans
- 25 laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est capable de se différencier en ostéoblastes, chondrocytes, et adipocytes.
4. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 1, exprimant en outre au moins l'un des gènes choisis dans le groupe constitué par : CREB1, DIO2, IRS1, MAPK14, NRF1, FOXC2, PPARD, PGC1-A, PGC1-B, PRDM16, SRC, UCP1, et WNT5A.
 5. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 4, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est dérivée d'un nouveau-né de sexe masculin âgé d'un jour.
 6. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 4, dans laquelle la cellule souche de tissu adipeux brun néonatal humain isolé est capable de se différencier en ostéoblastes, chondrocytes, et adipocytes.
 7. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 1, exprimant en outre au moins l'un des gènes choisis dans le groupe constitué par : UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, et WNT5A (REFX).
 8. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 7, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est dérivée d'un nouveau-né de sexe masculin âgé d'un jour.
 9. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 7, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est capable de se différencier en ostéoblastes, chondrocytes, et adipocytes.
 10. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon les revendications 1, 4, ou 7, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est positive aux marqueurs de surface cellulaire suivants : CD9, SSEA4, CD44, CD90, CD166, et CD73, et est négative aux marqueurs de surface cellulaire suivants : CD14, CD34, CD45, et STRO-1.
 11. Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 10, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est dérivée d'un nouveau-né de sexe masculin âgé d'un jour.

- 12.** Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon la revendication 10, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est capable de se différencier en ostéoblastes, chondrocytes, et adipocytes. 5
- 13.** Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon les revendications 1, 4, 7, ou 10, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est immortalisée. 10
- 14.** Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon les revendications 1, 4, 7, 10, ou 13, dans laquelle la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est transfectée. 15
- 15.** Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon les revendications 1, 4, 7, 10, 13, ou 14 exprimant en outre au moins l'un des gènes choisis dans le groupe constitué par : GATA2, KLF2, et KLF3. 20
25
- 16.** Lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon l'une quelconque des revendications 1 à 15 pour l'utilisation dans le traitement d'un trouble métabolique, par exemple l'obésité et / ou le diabète, chez un patient, dans laquelle la lignée cellulaire est cultivée sur un échafaudage, pour exemple une matrice extracellulaire poreuse. 30
- 17.** Procédé de criblage de composés médicamenteux, le procédé comprenant : 35
- la fourniture de la lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon l'une quelconque des revendications 1 à 16 ;
la mise en contact de la lignée de cellules souches de tissu adipeux brun néonatal humain isolé avec un composé médicamenteux candidat ; et
l'observation de l'effet du composé médicamenteux sur la lignée de cellules souches de tissu adipeux brun néonatal humain isolé. 40
45
- 18.** Procédé selon la revendication 17, dans lequel la lignée de cellules souches de tissu adipeux brun néonatal humain isolé est immortalisée. 50
- 19.** Construction implantable, comprenant :
- un échafaudage ; et
la lignée de cellules souches de tissu adipeux brun néonatal humain isolé selon l'une quelconque des revendications 1 à 16 mise en culture sur l'échafaudage. 55




FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2F



FIG. 2E

EP 2 986 714 B1




FIG. 3A-1

EP 2 986 714 B1




FIG. 3A-2

EP 2 986 714 B1





FIG. 3A-3

	CD90	CD166	STRO-1	CD45	CD133	CD34	SSEA-4	CD44	CD106	CD80
	BADSC	99.6 100	0	0	0	0	97.7	100	0	0
	WADSC	98.9 98.9	1.3	1	0.7	2	8.8	100	1.6	2
	LIN	DR,DP,DQ	CD73	CD117	CD105	A,B,C	CD86	CD63	CD9	
	BADSC	1.4 0	100	0	98.3	100	0	86	100	
	WADSC	11 0.5	99	1	68.3	86	2	99	95	

FIG. 3B






FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B

FACS DATA




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 6




FIG. 7




FIG.
8



FIG. 9




FIG. 10




FIG. 1




FIG. 12A




FIG. 12B




FIG. 13

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 61906087 [0001]
- US 61813771 B [0001]

Non-patent literature cited in the description

- **PATEL AMIT N et al.** Putative Population of Adipose-Derived Stem cells Isolated From Mediastinal Tissue During Cardiac Surgery. *CELL TRANSPLANTATION*, 02 April 2012, vol. 22 (3), 507-511 [0003]
- **BOSTROM et al.** A PGC1- α -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature*, 01 January 2012, vol. 481 (7382), 463-468 [0004]